Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE.
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, which reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits primarily bacteriostatic activity against susceptible gram-positive cocci and anaerobes.
Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. Benzoyl peroxide is an oxidizing agent with bactericidal activity against Propionibacterium acnes, and also has keratolytic and comedolytic effects.
Clindamycin 600-2700 mg/day IV divided every 6-8 hours. For severe infections, up to 4800 mg/day IV may be given.
Apply a thin film to affected areas twice daily (morning and evening).
None Documented
None Documented
The terminal elimination half-life is approximately 2.4-3.0 hours in adults with normal renal and hepatic function; prolonged to 3-6 hours in hepatic impairment and up to 8-14 hours in severe hepatic disease.
Terminal elimination half-life of clindamycin after topical application is approximately 2.4 hours. However, due to slow release from skin depot, effective half-life extends to 6–12 hours, supporting twice-daily dosing. Benzoyl peroxide has a very short half-life (<1 minute) on skin due to rapid decomposition; systemic half-life of benzoic acid is ~0.9 hours.
Clindamycin is primarily eliminated via hepatic metabolism; approximately 10% is excreted unchanged in urine, 3.6% in feces, and the remainder as inactive metabolites in bile and urine.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. After topical application, systemic absorption is minimal (approximately 10% of applied dose). The absorbed clindamycin is primarily excreted via the kidneys (10% unchanged, 3% as metabolites) and biliary/fecal routes (approximately 4%). Benzoyl peroxide is converted to benzoic acid, which is up to 87% excreted in urine as hippuric acid after conjugation with glycine. Overall, for the combination, renal excretion accounts for ~10%, biliary/fecal ~4%, remainder remains unabsorbed or metabolized locally.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic